PRMT5 and pancreatic ductal adenocarcinoma: PRMT5 as an anti-cancer target has gained significant interest in recent years and high levels of PRMT5 protein are associated with worse survival outcomes across multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC) [19–24].